Showing 61 - 70 of 227
Persistent link: https://www.econbiz.de/10014457646
Persistent link: https://www.econbiz.de/10015061619
The Indian pharmaceutical industry’s exports began to exceed its imports in the late 1980s. Since then, exports have grown rapidly, and the leading Indian firms have become significant exporters of generic drugs to the most advanced markets, including the U.S. As the Indian pharmaceutical...
Persistent link: https://www.econbiz.de/10009441088
How do private returns to inventive activity change when IPR regimes are substantially strengthened? Our paper investigates this question by looking at the impact of patent reforms in India on India-based pharmaceutical companies. In a fundamental policy shift, India agreed to introduce product...
Persistent link: https://www.econbiz.de/10009441232
Persistent link: https://www.econbiz.de/10009758399
Persistent link: https://www.econbiz.de/10011563790
Persistent link: https://www.econbiz.de/10010421600
Persistent link: https://www.econbiz.de/10009234148
In February 2017, India capped the retail price of coronary stents and restricted the channel margin to bring Percutaneous Transluminal Coronary Angioplasty (PTCA) procedure, which uses coronary stents, within reach of millions of patients who previously could not afford it. Prior research shows...
Persistent link: https://www.econbiz.de/10012844710
We use The Patents (Amendment) Act, 2002 in India as a quasi-natural experiment to identify the causal effect of higher incentives for innovation on a firm's compensation structure. We find that stronger intellectual property (IP) protection has a sharper impact on the demand for managerial...
Persistent link: https://www.econbiz.de/10012901099